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INTRODUCTION
 The red numbers on your alarm read two o’clock AM, but you’re wide awake. A dull ache 
below your ribs has tossed you from the blissful ignorance of sleep into the painful reality of an-
other nocturnal attack. As the pale streaks of daylight appear, you grit your teeth in agony while 
the ambulance goes over yet another bump in its rush to get you to the emergency room. A blur of 
white coats, lab tests, and CT scans, and then you’re staring into the bright lights above the oper-
ating table as the nurses prepare you for emergency gallbladder surgery. “Does it have to be this 
way?” you wonder, “Is there no other option?” The purpose of this paper is to answer just such a 
question. After clarifying gallbladder anatomy and the etiology of gallstone disease, it will evalu-
ate surgical and nonsurgical options for the treatment of gallstones. In the course of the discussion, 
it will examine the mechanism of action, efficacy, and safety of each treatment option. Once the 
analysis is complete, it will be possible to conclude if there are nonsurgical therapies that may be 
preferred over surgical removal of the gallbladder for relief of gallstone disease.
 
Gallbladder Anatomy And Physiology
 The gallbladder is a pear-shaped organ that can be found underneath the right lobe of the 
liver. Its function is to store the bile secreted by the liver and then, in turn, secrete this bile into 
the small intestine to aid in digestion of fats. Bile is composed of over 95% water with bile acids, 
phospholipids, cholesterol, bile pigments, and bicarbonate ions dissolved within (Portincasa et al, 
2009). The general physiological purpose of bile acids is to emulsify dietary fats in the small in-
testine, thus aiding in the digestion 
process. This paper, though, will 
focus on the role of bile acids and 
phospholipids in solubilizing cho-
lesterol in bile. While cholesterol 
is the building block of bile acids, 
it is also secreted unchanged into 
bile in order to maintain cholesterol 
homeostasis in the blood. The syn-
thesis of bile acids and the danger 
of excessive amounts of cholesterol 
will be discussed in subsequent sec-
tions. Bile pigments are composed 
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primarily of bilirubin, which is a breakdown product of hemoglobin. By secreting bilirubin into 
bile, the liver ensures that toxic levels do not build up in the body and are instead eliminated in 
the feces. Finally, bicarbonate ions are secreted by the pancreas into the bile to neutralize the acid 
entering the small intestine from the stomach (Widmaier et al, 2008). 
 While the liver is always in the process of secreting bile, not all this bile travels directly to 
the small intestine. At the point where the common bile duct joins the pancreatic duct and empties 
into the duodenum, a ring of smooth muscle surrounds the duct and prevents the release of bile. As 
long as this ring of muscle, the sphincter of Oddi, remains contracted, bile secreted from the liver 
is shunted into the gallbladder for storage. In the gallbladder, the dilute hepatic bile is concentrated 
many times over as salts and water are reabsorbed into the blood. Bile secretion from the gallblad-
der is controlled by a hormone called cholecystokinin, or CCK. After a fatty meal, the presence of 
fatty acids and amino acids in the small intestine stimulate the release of CCK into the blood. From 
there, the hormone travels to the gallbladder to stimulate its contraction, and to the sphincter of 
Oddi to stimulate its relaxation. This dual action allows the gallbladder to release its store of bile 
into the cystic duct, and the bile continues through the common bile duct and sphincter of Oddi to 
its final destination in the duodenum (Widmaier et al, 2008). It is only when problems arise in this 
chain of events that normal physiology is interrupted and gallstone disease develops.
Bile Acid Synthesis And Metabolism 
 In order to understand the ensuing discussion of gallstone pathogenesis, a preliminary dis-
cussion of bile acid chemistry is necessary. Bile acid synthesis is the primary method by which 
cholesterol is catabolized, or broken down. However, bile acids are not simply metabolites of an 
organic substance. They have their own unique roles—numerous functions which scientists are 
continuously clarifying and expanding.  The fascinating phenomenon of bile acid synthesis con-
verts a completely hydrophobic molecule into an amphiphile which can solubilize and transport 
nutrients, fats, and vitamins while also functioning as a powerful receptor ligand in various sig-
naling pathways. The process of synthesizing bile acids from cholesterol is a multistep sequence 
catalyzed by a host of different enzymes. The liver is the only organ in the body that boasts all 
fourteen enzymes required for this de novo synthesis of bile acids (Chiang, 2009). 
 The first step in the classic pathway of bile acid synthe-
sis is to add a hydroxyl group to position 7 of the cholesterol 
steroid nucleus. This reaction is catalyzed by the rate limiting 
enzyme, cholesterol 7α-hydroxylase, abbreviated CYP7A1. 
At this point, the pathway diverges to form the two most com-
mon human bile acids, cholic acid (CA) and chenodeoxycho-
lic acid (CDCA). To create the former, sterol 12α-hydroxylase 
(CYP8B1) is employed to add a hydroxyl group to position 8 
of the steroid nucleus.  The precursors of CDCA do not need 
an additional hydroxylation and proceed to the next step in the 
sequence. Once the cholesterol double bond is reduced by en-
zymes in the cytosol of the hepatocyte, mitochondrial sterol 
27-hydroxylase (CYP27A1) can add a hydroxyl group to posi-
tion 27 of the cholesterol side chain. This alcohol is then further 
oxidized to an aldehyde, and finally to a carboxylic acid, where-








Fig. 2 Bile acid synthesis (see 
text for explanation).  
(Adapted from Chiang, 2009) 
 
 
Figure 2. Bile acid synthesis (see 
text for explanation). (Adapted 
from Chiang, 2009)
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side chain shortening. In the peroxisomes, a three carbon unit is cleaved from the original side 
chain to form the C-24 bile acid from the C-27 cholesterol molecule. The basic backbone of the 
bile acids has thus been created, but most are conjugated to hydrophilic side chains derived from 
amino acids to increase their solubility in bile. Glycine and taurine (derived from the amino acid 
cysteine) are conjugated to the carboxylic acid side chain of the bile acids by means of their amino 
groups. The enzymes BACA (bile acid-CoA synthase) and BAAT (bile acid-amino acid transfer-
ase) facilitate this process and create the glyco- or tauro-conjugated CA or CDCA (Monte et al, 
2009). 
 An interesting point is that this developed synthesis path-
way is only employed for 5% of the bile acids that are secreted 
into bile (Portincasa et al, 2009). This is due to the recycling effect 
known as enterohepatic circulation. The bile acids synthesized by 
the liver are termed primary bile acids and are further modified by 
intestinal bacteria to their secondary bile acid counterparts. Both 
primary and secondary bile acids are then actively absorbed in the 
distal ileum, the last part of the small intestine. A transport protein 
coupled to sodium reabsorption transports the bile acids across 
the epithelial cells lining the intestine to the hepatic portal vein 
(Chiang, 2009). Upon reaching the liver, bile acids are taken up 
by hepatocytes where they prevent further bile acid synthesis by 
inhibiting the rate limiting enzyme CYP7A1 (Monte et al, 2009). 
These recycled bile acids are then used again in the secretion of 
bile. While some bile acids are inevitably lost in the feces, over 
95% are recovered via enterohepatic circulation, accounting for 
the minimal de novo synthesis of bile acids in the liver.  
Gallstone Pathogenesis
 Gallstone disease is one of the most common and most costly digestive diseases affecting 
Western industrialized countries. In a large epidemiologic study, the third National Health and Nu-
tritional Examination Survey (NHANES III) found that the overall prevalence of gallstones was 
7.9% in men and 16.6% in women in the United States. The disease was more dominant among 
Native Americans than other ethnic groups, indicating that genetics may play a role. Incidence 
of gallstones was comparable in European countries but much lower among Asians and Africans 
(Paumgartner and Greenberger, 2009). With over one million new cases of gallstones being dis-
covered every year, scientists continue to research the contributing factors of gallstone disease in 
the hopes of preventing future diagnoses (Portincasa et al, 2009).  
 All arrows seem to point to cholesterol as the primary culprit of gallstone disease, or cho-
lelithiasis. Radiographic scans have enabled doctors and scientists alike to characterize 80% of 
diagnosed gallstones as cholesterol stones. The pathogenic mechanisms that contribute to the for-
mation of gallstones, then, must be connected to cholesterol metabolism. Indeed, the hydrophobic 
cholesterol molecule is not soluble in bile and must be maintained in proper proportion with the 
other components of bile (namely, bile acids and phospholipids) in order to remain in solution 
(Portincasa et al, 2009). 
 Bile acids have been shown to be amphiphiles, that is, they are detergent-like molecules 
with both lipophilic and hydrophilic properties. As mentioned, the ringed steroid nucleus forms 
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Figure 3. Chemical structures of 
cholesterol and the primary bile 
acids
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the lipophilic face of the molecule while the hydroxyl groups and conjugated side chain create 
a hydrophilic face. If the levels of bile acids exceed a certain value, termed the critical micelle 
concentration (CMC), they will self-assemble into simple micelles. These structures are sphere-
like shapes consisting of a monolayer of bile acids surrounding cholesterol molecules sequestered 
within. The hydrophobic face of the bile acids faces inwards towards the lipophilic cholesterol, 
while the hydrophilic face is oriented outwards facing the aqueous medium of bile (Portincasa et 
al, 2009). 
 Phospholipids are another kind of amphiphile composed 
of long chain fatty acids bound to glycerol and polar phosphate 
groups on one end. They form a phospholipid bilayer that sur-
rounds cholesterol molecules in unilamellar vesicles. These 
vesicles are unstable, but with the addition of bile acids, will 
form water soluble “mixed micelles” that can solubilize tri-
ple the amount of cholesterol that simple micelles solubilize 
(Portincasa et al, 2009). Thus, if all the biliary components are 
in proper proportion, cholesterol will remain in solution and no 
disease will occur. 
 The problem arises when bile is supersaturated with 
cholesterol so that the cholesterol exceeds the solubilizing ca-
pacity of bile acids and phospholipids. This can occur due to excess cholesterol or insufficient 
amounts of bile acids or phospholipids. Whatever the reason, if all the unilamellar vesicles cannot 
be converted into the more stable mixed micelles, unstable cholesterol-rich vesicles remain in the 
bile. These vesicles are in a state of delicate equilibrium and can easily aggregate to form large 
multilamellar vesicles. The multilamellar vesicles are even less stable than their counterparts and 
cannot prevent the cholesterol molecules they hold from precipitating and forming cholesterol 
crystals (Paumgartner and Greenberger, 2009). Cholesterol crystals have traditionally been de-
scribed as rhomboid monohydrate crystals with a notch missing from one corner. Recent studies 
have shown that in the early stages of crystal formation, cholesterol may form anhydrous crystals 
shaped like needles, spirals, or tubules (Dowling, 2000). Cholesterol crystals that get stuck in a 
mucin gel lining the gallbladder will aggregate, giving rise to mature gallstones (Paumgartner and 
Greenberger, 2009).
 Different proteins have been identified as being responsible for transporting each specific 
element of bile from the interior of the hepatocyte to the bile canaliculus. These proteins are part 
Figure 4. Micelle Figure 6. Vesicle
Figure 7. Gallstone pathogenesis 
(Paumgartner and Greenberger, 
2009)
Figure 5. Space filling model of cholic 
acid showing hydrophobic 
face(red) and hydrophilic face(blue). 
(Portincasa et al, 2009)
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of a superfamily of transport proteins called ATP-binding cassette transporters (ABC transporters) 
that use the energy from ATP hydrolysis for translocation of various substances across a biological 
membrane. Cholesterol secretion into bile is controlled by ABCG5/G8, while the bile salt export 
pump (BSEP; ABCB11) regulates the secretion of bile acids. Multidrug resistant p-glycoprotein 3 
(MDR3;ABCB4) transports phosphatidylcholine, the primary phospholipid in bile, from the inner 
leaflet to the outer leaflet of the canalicular membrane. Emerging studies reveal that a genetic defect 
in the cholesterol transporter, ABCG5/G8, predisposes its carrier to gallstones (Paumgartner and 
Greenberger, 2009). Additionally, one team identified a mutation in the gene encoding the ABCB4 
transporter protein (Wang et al, 2009). This mutation results in decreased phospholipid levels in 
bile and has been named “gallbladder disease 1” (GBD1). Other risk factors of gallstone disease 
include obesity, where excessive amounts of cholesterol supersaturate the bile, and pregnancy, 
where increased estrogen levels also result in elevated levels of cholesterol in bile (Paumgartner 
and Greenberger, 2009).
 One final factor implicated in the pathogenesis of gallstones is impaired gallbladder empty-
ing. The sequence outlined above that accounts for the formation of gallstones from cholesterol-
rich unilamellar vesicles cannot occur if these vesicles and the cholesterol crystals they produce 
are expelled from the gallbladder in a timely fashion. Normally, the time required for gallstones to 
develop from supersaturated bile is longer than the amount of time the bile sits in the gallbladder! 
However, if the contractility of the gallbladder is diminished in a condition known as gallbladder 
stasis, then prolonged retention of supersaturated bile allows gallstones to grow. This condition 
is associated with fasting and parenteral nutrition, where there are no nutrients in the intestine 
to stimulate the release of CCK, which will, in turn, stimulate the gallbladder to contract. Addi-
tionally, increased levels of progesterone during pregnancy inhibit smooth muscle contraction, as 
do certain drugs, thereby impairing gallbladder emptying (Paumgartner and Greenberger, 2009). 
Later sections will discuss options that have been proposed to increase gallbladder contractility, 
and thus prevent the formation of gallstones.
Figure 8. Biliary transport proteins and gallstone pathogenesis. 
(Paumgartner and Greenberger, 2009)
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To Treat Or Not To Treat?
 Most patients that are diagnosed with gallstones do not require any immediate treatment 
(Lanzini et al, 1994). Since many gallstones are found during imaging studies done for other gas-
trointestinal conditions, and the patients are otherwise unaware of their gallstones, these gallstones 
are considered asymptomatic (Paumgartner and Greenberger, 2009). Patients with asymptomatic 
gallstones have a very low likelihood of developing any pain or complications from their condi-
tion. Only a small subgroup of asymptomatic patients are at increased risk of developing compli-
cations due to individual characteristics. This group of patients will not be discussed in this paper. 
In general, then, treatment of asymptomatic gallstones is ill-advised, as the risks outweigh any 
potential benefits. The only recommendations offered are that patients be monitored by observa-
tion alone to ensure that they remain asymptomatic (Lanzini et al, 1994). 
 Symptomatic gallstone disease, on the other hand, is a definite indication for treatment. Pa-
tients with symptomatic gallstones typically present with intense pain in the upper right quadrant 
of the abdomen that often radiates to the angle of the right scapula and/or shoulder (Portincasa et 
al, 2009). The pain is usually persistent despite its common classification as biliary colic, a misno-
mer suggesting intermittent pain. Rapid onset of pain is common and duration of symptoms ranges 
from fifteen minutes to a few hours after which the pain subsides gradually or rapidly. Patients may 
complain of associated nausea and other nonspecific symptoms of indigestion and may feel the 
urge to walk. Many patients are awakened by nocturnal symptoms, often after eating fatty foods. 
The pain of symptomatic gallstone disease is a visceral pain triggered by gallstones lodged in the 
cystic duct, common bile duct, or ampulla of Vater (the enlargement of the common bile duct and 
pancreatic duct as they enter the duodenum at the sphincter of Oddi). As the gallbladder contracts 
and releases bile, gallstones may migrate along with the bile into the aforementioned passageways. 
When they get stuck in the ducts, they block the normal flow of bile, thus causing distention of the 
biliary tract and gallbladder. Such distention activates visceral sensory neurons that communicate 
a feeling of pain to the patient (Paumgartner and Greenberger, 2009). Once pain sets in, patients 
should commence fasting to prevent release of CCK and further contraction of the gallbladder 
causing more pain. Narcotic analgesics, such as meperidine, or non-steroidal anti-inflammatory 
drugs (NSAIDs), such as ketorolac or ibuprofen, are indicated to relieve biliary pain (Portincasa 
et al, 2009). Although direct relief of biliary pain is a vital component of managing symptomatic 
gallstone disease, this paper will focus on methods of eliminating or reducing the gallstones them-
selves in an effort to relieve their associated pain.
   
Laparoscopic Cholecystectomy
 As the opening paragraph suggests, surgical removal of the gallbladder is considered first 
line treatment for symptomatic gallstone disease. In the days of open cholecystectomy, many pa-
tients were understandably concerned about the mortality risks, prolonged hospital stay, extended 
recovery time, and unattractive scars of the operation. The tendency to seek alternative, medical 
options to treatment was therefore high. However, with the advent of laparoscopic cholecystecto-
mies in the late 1980s, attitudes towards surgical treatment have dramatically improved (Lanzini 
et al, 1994). 
 As opposed to the large incision required for open cholecystectomy, laparoscopic tech-
nique only necessitates four small incisions (5-10 mm) in the abdomen. The surgeon then inserts 
a thin, lighted tube, called a laparoscope, connected to a video monitor, and the tools that he will 
use during the operation (Brandon et al, 1991). This technique requires considerable surgical skill, 
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but has not been shown to increase the inherent risks of mortality and complications involved in 
surgically resecting the gallbladder. One landmark study even noted decreased risks of some com-
plications after laparoscopic cholecystectomy, as compared with its traditional counterpart. “Lap 
chole,” as it is known, effectively reduces the hospital stay of open cholecystectomy patients by 
up to three days and recovery time by up to three weeks. By returning to work early, laparoscopic 
patients have reduced the overall costs of the operation by 18% (Paumgartner and Greenberger, 
2009). This minimally invasive procedure has demonstrated cosmetic and economic appeal over 
the conventional open cholecystectomy but an obvious question remains. To what degree does the 
surgery guarantee relief of biliary pain, its primary indication?
 One study evaluated 118 patients who had undergone cholecystectomies, whether lapa-
roscopic or traditional, and found that 93% of participants were satisfied with the results of the 
procedure. Although a significant number of patients reported persistent abdominal pain even after 
the operation, Vander Velpen et al classified these symptoms as unrelated to gallstone disease. 
By comparing the number of patients with preoperative symptoms to the number complaining of 
postoperative symptoms, the researchers determined that fat intolerance, flatulent dyspepsia, and 
nagging abdominal pain were unrelated to gallstone disease. They claimed, in keeping with earlier 
studies, that these symptoms were caused by unrelated gastrointestinal disturbances prevalent in 
gallstone patients and were therefore unaffected by removing the diseased gallbladder. In contrast, 
nausea, vomiting, colicky abdominal pain, back pain, and heartburn appear to be secondary to 
gallstone disease and were more reliably relieved by cholecystectomy (Vander Velpen et al, 1993).
 Postcholecystectomy diarrhea may be the most distressing symptom that develops as a re-
sult of cholecystectomy. Vander Velpen et al found that 18% of their patients complained of PCD 
and traced it to malabsorption of fats due to changes in release of bile (1993). In a recent published 
work, Fisher et al offered their own pathogenic factors for PCD, but admitted that they could not 
be substantiated (2008). They found a similar incidence of PCD and correlated this increased inci-
dence with male patients, younger than 50 years of age, with elevated BMIs. Despite the disruptive 
nature of PCD, Vander Velpen et al have shown that most patients are nevertheless pleased with the 
outcomes of their cholecystectomies (1993).  
 Besides the specific nature of PCD, a persistence of nonspecific abdominal symptoms after 
surgical resection of the gallbladder is known as postcholecystectomy syndrome, or PCES. PCES 
is not well defined but may be associated with sphincter of Oddi dysfunction resulting from scar-
ring during cholecystectomy. Patients who complain of continued abdominal pain also do not 
realize that gallstones may still be forming in the common bile duct, even though their gallblad-
der has been removed. Endoscopic tests must be performed to diagnose and treat PCES properly 
(Comstock, 2008). 
 In one study, a group of 100 patients awaiting laparoscopic cholecystectomy was fol-
lowed over the course of their operation and beyond. After evaluating individual characteristics 
in patients that remained symptomatic after surgery, Luman et al were able to identify specific 
predictors of PCES (1996). They urged surgeons to reconsider accepting patients with preop-
erative constipation, bloating, or psychotropic medication histories. These patients seemed more 
likely to develop PCES, and for good reason. Histological studies of the resected gallbladders 
revealed that many of them were not inflamed. Therefore, the abdominal pain that was diag-
nosed as biliary pain may have been due to underlying gastrointestinal disorders, such as irri-
table bowel disease. This finding matches the opinion of Vander Velpen et al cited above, and is 
confirmed by a history of anxiety and depression among many IBD patients (Luman et al, 1996). 
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 Just over a year ago, another analysis confirmed these results and advocated more individ-
ual patient assessment before lap chole is categorically advised. Mertens et al proposed the novel 
notion that expectant management of gallstone disease may be preferred to surgical treatment in a 
group of high risk patients (2010). As found previously, individuals with dyspeptic symptoms (bad 
taste, heartburn, under abdominal pain, diarrhoea and flatulence) and those using psychotropic 
medications are at increased risk of unsuccessful cholecystectomies and should therefore be evalu-
ated differently (Mertens et al, 2010). 
 In general, then, lap chole is considered the safe and effective gold standard for treating 
symptomatic gallstone disease. However, the decision to undergo surgery has to be made on an 
individual basis. Health care practitioners must educate patients on the potential risks of unsuc-
cessful relief of symptoms or the onset of new symptoms, such as PCD. This is especially the 
case in patient populations with characteristics known to predict PCES and the like. Patients can 
then weigh the pros and cons of laparoscopic cholecystectomy and decide whether or not to go 
ahead with the procedure. Since gallstone disease is relatively benign, and watchful waiting has 
no increased risk of complications, patients may prefer such an option (Konikoff, 2003). The rest 
of this paper will discuss medical alternatives that patients and providers may wish to pursue as 
alternative to surgery in the treatment of symptomatic gallstone disease.  
 
Ursodeoxycholic Acid (UDCA)
 In 1936, a Japanese team identified the structure of 
ursodeoxycholic acid, the 7β-hydroxy epimer of chenode-
oxycholic acid (Hofman and Roda, 1984). Where the hy-
droxyl group on C7 of CDCA has an alpha configuration 
(dashed wedge) and faces down and out of the plane of the 
steroid nucleus, the C7 hydroxyl group in UDCA acid has 
a beta stereochemistry (solid wedge) in line with the ste-
roid nucleus. This minor change in stereochemistry has led 
to major differences in clinical findings, which will be dis-
cussed shortly. Ursodeoxycholic acid is found to only a lim-
ited degree in the bile of healthy individuals (Portincasa et al, 2009). However, it is the major bile 
acid of the black bear, explaining the origin of its unusual name. The curative nature of bear bile 
has been known for centuries, thus the Japanese who first established UDCA sought to investigate 
its medicinal effects (Hofman and Roda, 1984). As UDCA became more popular, other scientists 
joined in this effort, in the hopes of finding a new oral therapy to treat symptomatic gallstone 
disease.  While CDCA had been the oral bile acid in use since the 1970s, it was later proven to be 
associated with increased liver enzymes, elevated LDL, and the development of bile acid-induced 
diarrhea (Portincasa et al, 2009). The manufacturer’s information for chenodiol, the generic name 
for CDCA, now contains a black box warning with this evidence (“Chenodiol”). Scientists hoped 
that UDCA would preserve the efficacy of CDCA in dissolving cholesterol gallstone, while mini-
mizing its adverse effects. 
 Indeed, if patients are carefully selected for treatment with UDCA, complete dissolution of 
gallstones can be accomplished in about 90% of cases. Proper inclusion criteria for UDCA treat-
ment include the presence of radiolucent cholesterol stones, preferably less than 5 mm, and a func-
tioning gallbladder (Portincasa et al, 2009). Cholesterol stones are generally radiolucent, thus they 
allow the passage of x-rays and cannot be seen on regular x-ray films. If the gallstones are com-
Figure 9. Chemical structure of UDCA
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posed mostly of pigments or calcium, such radiopaque stones will show up on x-rays and are not 
indicated for oral dissolution with UDCA (Bouchier, 1983). Patients with smaller gallstones have 
a greater chance of complete dissolution in a reasonable time frame (around six months), because 
of the greater surface area and greater exposure to dissolving effects of the drug (Lanzini et al, 
1994). Although patients with stones up to 10 mm are indicated for UDCA treatment, their length 
of therapy extends to one year and likelihood of complete dissolution drops to about 50% (Portin-
casa et al, 2009). Finally, a functioning gallbladder is necessary for UDCA treatment, to ensure that 
the drug will work properly and that its effects can be monitored radiologically (Bouchier, 1983). 
Thus, if patients meet the inclusion criteria for UDCA therapy, they can hope to benefit from the 
newer bile acid on the market.  To confirm this hypothesis, Meredith et al established that UDCA 
is at least as effective as CDCA in treating gallstones, but that it does so at lower doses and with 
fewer side effects (1982). All that remains to be seen is the mechanism by which ursodeoxycholic 
acid succeeds in dissolving cholesterol gallstones.  
 If supersaturated bile is a prerequisite for gall-
stone formation, as discussed above, then unsaturat-
ed bile is a prerequisite for dissolution of preformed 
gallstones. Indeed, UDCA has been found to unsatu-
rate gallbladder bile, although the exact mechanism 
is still unclear. It seems that by inhibiting cholesterol 
reabsorption from the intestines, cholesterol secre-
tion into bile is decreased, and an unsaturated bile 
results (Portincasa et al, 2009). One team suggested 
that UDCA simply improves the incorporation of cho-
lesterol into mixed micelles, thereby reducing biliary 
cholesterol saturation (Guarino et al, 2007). When cho-
lesterol crystals are exposed to unsaturated bile in the 
gallbladder, they slowly dissolve over time.  Fig. 9 compares typical cholesterol crystals in patients 
with gallstones(A,B) to the  atypical crystals observed during UDCA therapy(C,D). The atypical 
nature of the bottom crystals indicates that they have been chipped away at by the unsaturated bile 
created by UDCA treatment (Portincasa et al, 2009). 
 One interesting theory proposed to account for UDCA-dependent unsaturation of bile in-
volves the ABC transporters mentioned earlier. The genes that regulate the expression of BSEP and 
MDR3 are in turn regulated by transcription factors. 
Transcription factors are receptors that bind to specific 
ligands, undergo a conformational change, and migrate 
to the nucleus where they regulate expression of specif-
ic genes. The ligand-activated transcription factor that 
is responsible for the expression of BSEP and MDR3 
is known as farnesoid X receptor, FXR. FXR has been 
shown to upregulate BSEP and MDR3, thus creating 
increased levels of bile acids and phospholipids in gall-
bladder bile (Portincasa et al, 2009). Since UDCA is a 
ligand, albeit weak, of FXR, its binding to FXR may 
explain its unsaturation of gallbladder bile (Sauter et 
al, 2004). If the ratio of bile acids and phospholipids to 
Figure 10. Cholesterol crystals (see text for 
explanation). (Portincasa et al, 2009)
Figure 11. Transcription factors regu-
lating biliary secretion. BS=Bile salts, 
PC=Phosphatidylcholine, Chol=Cholesterol. 
(Portincasa et al, 2009)
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cholesterol is increased, then more cholesterol can be dissolved in mixed micelles and the bile is 
considered unsaturated.  
 While supersaturation of bile certainly accounts for the pathogenesis of gallstones, gall-
bladder stasis is also implicated in this phenomenon. Therefore, improving the contractility of 
gallbladder can prevent gallstones from forming.  In terms of UDCA therapy, its effects on the 
saturation of bile and gallbladder motility are related. By reducing cholesterol saturation in bile, 
UDCA prevents cholesterol from impairing gallbladder motility. Whatever the reason for UDCA-
dependent unsaturation of bile, the end result is diminished levels of cholesterol in bile. Guarino 
et al proved that excess cholesterol in patients with gallstones tends to accumulate in the plasma 
membrane of muscle cells. The cholesterol molecules aggregate in caveolae, “high-cholesterol 
domains containing caveolin proteins and a variety of molecules involved in signal transduction 
pathways,” and sequester receptors located in these regions (2007). When ligands such as CCK 
attempt to stimulate receptors in the caveolae to cause gallbladder contraction, they are blocked by 
the excessive of amounts of cholesterol surrounding the receptors. Reducing levels of cholesterol 
will therefore prevent the accumulation of cholesterol in the plasma membrane of muscle cells. 
This will allow CCK to bind to its receptors and restore normal gallbladder contractility (Guarino 
et al, 2007).  In vitro studies have substantiated these theories, showing increased contraction with 
UDCA treatment, especially during long term therapy (Mas et al, 2007). Thus, by reducing levels 
of cholesterol, UDCA can effectively improve gallbladder motility. 
 Other authors have suggested a different mechanism by which UDCA improves gallblad-
der contractility. In this case, it not linked to a reduction of cholesterol saturation, but to a reduction 
of deoxycholic acid. DCA is secondary bile acid and is formed by dehydroxylation of the primary 
cholic acid. A hydrophobic bile acid, DCA is associated with impaired gallbladder emptying and 
cholesterol hypersecretion into bile (Dowling, 2000). Recent findings suggest that UDCA may 
prevent these detrimental effects of DCA (Portincasa et al, 2009). Specifically, UDCA has been 
shown to induce expression of CYP3A4, an enzyme responsible for bile acid metabolism. By in-
creasing levels of CYP3A4, UDCA may increase breakdown of toxic, hydrophobic bile acids into 
less toxic, hydrophilic bile acids. UDCA can thus decrease levels of DCA and prevent gallbladder 
stasis and the attendant formation of gallstones (Paumgartner and Beuers, 2004). 
 The optimal dosage for UDCA therapy is 10-15 mg/kg/day. This dose is best administered 
at bedtime to maximize the effect of the drug (Portincasa et al, 2009). Normal physiology dictates 
that enterohepatic circulation is interrupted at night. This is will decrease the secretion of bile ac-
ids into the bile and increase the proportion of biliary cholesterol. However, UDCA maintains the 
secretion of bile acids overnight, thereby preventing secretion of supersaturated bile. It is therefore 
recommended to take a bedtime dose of UDCA in order to potentiate its effects (Lanzini et al, 
1988). 
 As opposed to CDCA, treatment with UDCA has little if no side effects. In a comparative 
study of chenodiol and ursodiol, the incidence of hepatotoxicity with UDCA was low and none 
of the patients developed diarrhea (Meredith et al, 1982). However, other studies indicate that a 
small percentage of patients may develop calcified rims surrounding their cholesterol gallstones. 
This would render the stones radiopaque and incompatible with further UDCA therapy. The big-
gest disadvantage of oral dissolution of gallstones with UDCA is the high risk of recurrence. Up to 
50% of patients treated with UDCA may find recurring gallstones as soon as 3-5 years after treat-
ment. Therefore, UDCA therapy is only advised for patients who refuse surgery, are not candidates 
for surgery, or have transient risk factors such as pregnancy or rapid weight loss (Portincasa et al, 
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2009). 
Extracorporeal Shock Wave Lithotripsy (Eswl)
 Lithotripsy is the practice of using soundwaves to break stones into smaller fragments. This 
technique was originally developed for use in treating kidney stones but was pioneered for use in 
gallstone treatment by Paumgartner and colleagues in the 1980s (Paumgartner, 2010). The theory 
behind this treatment was to reduce larger gallstones to a diameter of less than 3 mm that would 
then be indicated for treatment with UDCA. Lithotripsy is therefore an adjuvant, or supplemen-
tary, procedure meant to improve the efficacy of UDCA therapy (Lanzini et al, 1994). Performing 
ESWL before UDCA also increases the amount of patients who eventually qualify for UDCA 
therapy. Indeed, the selection criteria for ESWL with subsequent UDCA therapy are broader than 
those for UDCA therapy alone. In order to qualify for ESWL + UDCA, patients must have one 
radiolucent gallstone less than 20 mm and a functioning gallbladder (Paumgartner, 2010). If these 
criteria are met and a high energy lithotripter is used, the treatment is effective in two-thirds of the 
cases (Lanzini et al, 1994).
 Before the advent of laparoscopic cholecystectomy, ESWL was preferred over traditional 
cholecystectomy because of its enhanced safety profile. However, like oral bile acid therapy, the 
recurrence rate was high. The incidence of recurrence of gallstones at two years and ten years after 
ESWL treatment was 11-29% and 60–80% respectively (Paumgartner and Greenberger, 2009). 
Darzi et al concluded that “while ESWL has minimal side-effects it is associated with more limited 
selection criteria, a more prolonged treatment time, a higher failure rate, and a higher recurrence 
rate when compared with laparoscopic cholecystectomy” (1994). Therefore, when lap chole be-
came the gold standard for treating symptomatic gallstones and greatly reduced hospital stays and 
recovery time after surgery, ESWL became obsolete. Currently, ESWL is reserved for treating bile 
duct stones that have not responded to endoscopic treatment (Paumgartner, 2010).
Figure 12. Percentage of patients with complete gallstone dissolution at 6 and 12 months after 
extracorporeal shockwave lithotripsy (ESL) plus UDCA therapy (left), and UDCA alone (right) for 
single and multiple stones. (Lanzini et al, 1994)
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 Ezetimibe (Ezt) 
 Ezetimibe is a potent member of a new class of drugs that inhibit intestinal absorption of 
cholesterol. Although it is currently only indicated for reducing LDL levels in hyperlipidemia, 
research is underway to determine its potential for preventing and dissolving gallstones. Choles-
terol absorption from the intestine is a key step in the process of secreting cholesterol into bile. 
Although the liver can synthesize cholesterol from scratch, this de novo synthesis only contributes 
15% to the overall biliary cholesterol (Porincasa et al, 2009). The majority of biliary cholesterol 
is derived from dietary and recycled biliary cholesterol 
that are absorbed in the small intestine. After absorption, 
cholesterol is packaged with triglycerides into lipopro-
tein particles called chylomicrons. These particles lose 
their triglycerides to tissues as they migrate through the 
bloodstream, and are finally absorbed by hepatocytes as 
cholesterol-rich particles (Malloy and Kane, 2009). By 
reducing intestinal absorption of cholesterol, ezetimibe 
can effectively reduce the amounts of cholesterol that 
reach the liver for secretion into bile. 
 
 The mechanism of action of ezetimibe centers around a transport protein located in the 
brush border lining the small intestine. This protein has been recently characterized as NPC1L1 
(Niemann-Pick C1-like 1) and facilitates intestinal absorption of cholesterol through a multi-
step process (Fig. 14) (Portincasa et al, 2009). Ezetimibe binds to and inhibits NPC1L1, thereby 
effectively inhibiting absorption of dietary and biliary cholesterol. This, in turn, results in decreased 
Figure 13. Chemical structure of ezetimibe
Figure 14. The NPC1L1 protein recycles between the plasma membrane facing the extracellular space and the 
endocytic recycling compartment. In the presence of high extracellular cholesterol, cholesterol is incorporated into 
the plasma membrane and is sensed by cell surface-localized NPC1L1. Both NPC1L1 and cholesterol are then inter-
nalized together through clathrin/AP2-mediated endocytosis and stored within the endocytic recycling compart-
ment. If the intracellular cholesterol level is low, endocytic recycling compartment-localized NPC1L1 moves back to 
the plasma membrane along microfilaments and new cholesterol is absorbed. The key role of the inhibitor ezeti-
mibe (EZT) is shown at the center of the cell. EZT prevents NPC1L1 from entering the AP2-mediated clathrin-coated 
vesicles. At this stage, the endocytosis of NPC1L1 is inhibited and  cholesterol absorption is decreased (Portincasa 
et al, 2009).
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secretion of biliary cholesterol and an unsaturated bile. Studies in mice proved that ezetimibe ac-
complishes dissolution of gallstones by forming unsaturated micelles. As cholesterol present in 
the preformed gallstones is transferred to the unsaturated micelles, the stones become smaller and 
eventually dissolve. Additionally, reduced levels of biliary cholesterol can improve gallbladder 
motility in the same way that UDCA achieves this goal (Wang et al, 2008). Although the effects 
of ezetimibe on cholesterol saturation of bile have yet to be corroborated by studies in humans, 
its effects in mice have shown potential for a novel therapy in the treatment of gallstone disease. 
Dietary Phospholipids
 Based on an understanding of gallbladder physiology and biliary secretion, studies have 
been conducted to evaluate the effects of phospholipids on formation of cholesterol gallstones. 
One experiment found that in vitro supplementation of gallbladder biles with disaturated phospho-
lipids prolonged cholesterol nucleation time (Jungst et al, 1993). Nucleation time is understood 
as the number of days required for cholesterol monohydrate crystals to first appear in bile (Abey-
suriya et al, 2010). Jungst et al proposed that this prolonged nucleation time was due to two factors 
(1993). Firstly, increasing levels of phospholipids serves to decrease the proportion of cholesterol 
in bile. This lowers the cholesterol saturation of bile and slows formation of cholesterol gallstones. 
The second interesting phenomenon Jungst and his colleagues discovered was that phospholipids 
stabilized cholesterol vesicles by shifting the phase equilibrium towards mixed micelles (1993). As 
mentioned earlier, cholesterol-phospholipid vesicles are considered unstable while mixed micelles 
consisting of cholesterol, phospholipids, and bile acids are more stable and therefore less likely to 
allow the cholesterol to precipitate into crystals. Thus, in vitro supplementation with phospholipids 
has been shown to create a biliary environment better able to solubilize cholesterol and prolong 
formation of gallstones. While other studies confirm these beneficial results, clinical practitioners 
cannot yet advise their patients to supplement their diets with phospholipids (Moschetta et al, 
2001). Before such a recommendation can be made, further studies are needed in order to investi-
gate whether the published results can be reproduced in vivo. 
Summary Algorithm 
Figure 15. Algorithm 
for the manage-
ment of cholesterol 
gallstone disease. 




 The high prevalence of gallstone disease in Western countries renders it an important topic 
of discussion. Unfortunately, many people can relate to the opening question of whether or not to 
consent to surgical removal of the gallbladder. In light of this paper’s analysis of gallstone treat-
ments, this decision is no doubt easier. Those with asymptomatic gallstones need no active treat-
ment as long as they are routinely monitored and remain asymptomatic. It is clear that laparoscopic 
cholecystectomy is considered first line treatment for symptomatic gallstone disease. Although it 
poses a slight risk of mortality and complications, it is the most efficacious procedure for prevent-
ing recurrence of biliary pain and gallstones. Even the complaints of persistent abdominal pain 
following surgery have been shown to be associated with underlying conditions not related to 
gallstone disease. While UDCA and ESWL used to be standard alternatives to surgery, their pro-
longed length of therapy and high recurrence rate have rendered them virtually obsolete. They are 
reserved for patients who refuse surgery or for whom surgery poses increase risks. Novel therapies 
such as ezetimibe and dietary phospholipids are still being investigated and may prove to be main-
stay treatments in the future. 
 The bottom line emerging from the clinical studies canvassed in this paper is the need to 
evaluate each individual case before recommending an option for treatment. Personal character-
istics may indicate whether surgery is advisable or whether a medical option might be more suc-
cessful. Effective communication between the informed patient and the well-versed physician is 
crucial for selecting the most beneficial treatment option. If the suggestions presented here are 
employed, we may yet see a decline in the incidence of gallstone disease.  
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